A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment—USMIRC Group

TL;DR

This study shows that teclistamab is safe and effective for treating multiple myeloma patients with kidney issues, similar to those without.

Contribution

The study provides real-world evidence of teclistamab's safety and efficacy in multiple myeloma patients with baseline renal impairment.

Findings

Patients with renal impairment had comparable response rates and toxicity profiles to those without.

No significant differences in adverse events like cytokine release syndrome or infections were observed.

RI patients required more blood transfusions but had similar progression-free survival predictors.

Abstract

Teclistamab is a bispecific antibody used for treating relapsed/refractory multiple myeloma. The use of teclistamab in patients without renal impairment has demonstrated well-tolerated outcomes; however, its efficacy and safety in patients with renal impairment have yet to be closely explored. This retrospective study aimed to compare outcomes in patients with relapsed/refractory multiple myeloma with and without renal impairment who received teclistamab.

Background: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells and a rapidly evolving treatment landscape. Bispecific antibodies targeting B-cell maturation antigens (BCMA) have emerged as promising therapeutic options for relapsed and/or refractory multiple myeloma (RRMM). Methods: This retrospective study evaluated the efficacy and safety of teclistamab, a BCMA-directed bispecific antibody, in patients with RRMM with renal impairment (RI) at baseline compared to those without. Conducted across seven academic centers, the study included 195 patients with RRMM, of whom 34 had baseline RI. Results: Performance status, previous lines of treatment, and prior BCMA exposure were identified as significant predictors of progression-free survival. Notably, patients with RI demonstrated overall response rates and toxicity profiles comparable to those without RI, although they required more packed red blood cell transfusions. No statistically significant differences were observed in adverse events, including cytokine release syndrome and infections. Conclusions: Overall, the findings support the efficacy and safety of teclistamab in patients with RRMM and RI, highlighting the need for prospective clinical trials to optimize the treatment strategies for this population.

Figures